M86.29
BillableSubacute osteomyelitis, multiple sites
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is M86.29 an HCC code?
Yes. M86.29 maps to Bone/Joint/Muscle Infections/Necrosis under the CMS-HCC V28 risk adjustment model (and Bone/Joint/Muscle Infections/Necrosis under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for M86.29
For M86.29 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed M86.29 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
M86.29 is the ICD-10-CM diagnosis code for subacute osteomyelitis, multiple sites. A bone infection that develops over weeks to months affecting multiple bones or sites throughout the body simultaneously. M86.29 sits in the ICD-10-CM chapter for diseases of the musculoskeletal system and connective tissue (m00-m99), within the section covering other osteopathies (m86-m90).
Under the CMS-HCC V28 risk adjustment model, M86.29 maps to Bone/Joint/Muscle Infections/Necrosis (HCC 92) with a community, non-dual, aged base RAF weight of 0.209. Under the older V24 model, M86.29 mapped to the same category but with a base RAF weight of 0.482 — V28 recalibrated weights across the entire model. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code only when the infection clearly involves more than one anatomical site; document all affected locations. Because M86.29 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for M86.29 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Use this code only when the infection clearly involves more than one anatomical site; document all affected locations.
- •This code indicates systemic involvement, which may warrant investigation into underlying causes such as immunocompromise.
Clinical Significance
Subacute osteomyelitis involving multiple sites represents a serious intermediate-stage bone infection developing over weeks to months affecting several bone locations simultaneously. This multifocal involvement indicates more complex disease requiring aggressive treatment and close monitoring to prevent progression to chronic infection with significant morbidity and functional impairment.
Documentation Requirements
- ✓Documentation of subacute osteomyelitis affecting multiple sites
- ✓Clear identification of involvement at two or more distinct bone locations
- ✓Evidence of infection timeline consistent with subacute phase
- ✓Clinical presentation supporting multifocal bone infection
- ✓Imaging studies confirming osteomyelitis at multiple sites
- ✓Laboratory markers indicating ongoing systemic infection
- ✓Culture results and organism identification when possible
- ✓Assessment of overall functional impact and disease severity